Navigation Links
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Date:2/20/2013

The research was published early in the January issue of the journal Technology in Cancer Research and Treatment. The article describes experiments using ultrasonic molecular imaging (USMI) and Dynamic Contrast Enhanced-Perfusion Imaging (DCE-PI) to measure response to therapy for pancreatic cancer.

Paul Dayton, PhD, senior author says, "What we found is that using two non-invasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new non-invasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person's treatment to improve outcomes."

Dr. Dayton, an Associate Professor of Biomedical Engineering, worked with Jen Jen Yeh, MD, Associate Professor of Surgery and Pharmacology, to evaluate the imaging technologies on human pancreatic cancer in a pre-clinical model. Both faculty are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to characterize non-invasively the biologic processes at the cellular and molecular levels. It does this through the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a standard ultrasound system to detect signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a method used to non-invasively monitor the blood flow in the microcirculation. Since growing tumors require abnormally increased blood flow, changes in blood vessel structure or density can provide information regarding tumor malignancy.

The team used a drug that inhibits a protein specific to tumors. They then used the imaging tools to measure the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The results indicated that USMI was able to de
'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Preclinical studies use specialized ultrasound to detect presence of cancer
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Virology researcher awarded nearly $2 million to study chronic hepatitis E
4. New study shows how seals sleep with only half their brain at a time
5. Study shows that diet of resistant starch helps the body resist colorectal cancer
6. Breakthrough study opens door to broader biomedical applications for Raman spectroscopy
7. Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study
8. Yale Study links common chemicals to osteoarthritis
9. CU-Boulder amphibian study shows how biodiversity can protect against disease
10. Busy beavers give Canada geese a lift, study shows
11. Video study shows which fish clean up coral reefs, showing importance of biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/29/2014)... academics in the University of Bristol,s Nutrition and Behaviour ... calories into account when planning meals. , The research, ... of Ingestive Behavior Conference (SSIB 2014) in Seattle, USA ... we do. , The team was led by Professor ... Experimental Psychology. , As part of a Biotechnology and ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... BETHESDA, MD August 23, 2007 On August 16, the ... blood-thinner warfarin, sold under the brand name Coumadin. The new ... that may be safer for patients with variations in two ... through genetic testing, which may be a useful tool in ...
... Optics 2007 (FiO), the 91st Annual Meeting of the ... 16-20 in San Jose, Calif., alongside Laser Science XXIII, ... of Laser Science. Reporters interested in obtaining a ... at 202.416.1437, cmorri@osa.org . FiO RESEARCH ...
... system designed for brain tumor therapy has shown promising ... devised by University of Nottingham scientists. The project, conducted ... Human Development, will be featured in the September issue ... cancers is particularly difficult for a number of reasons, ...
Cached Biology News:American College of Medical Genetics responds to new FDA labeling decision for warfarin 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2
(Date:7/30/2014)... 2014 Selexis SA , a ... discovery and mammalian cell line development, announced today new ... will be presented at the 10th Annual Cell ... 8 – 10, 2014 at the Double Tree by ... following abstract will be presented during an oral presentation: ...
(Date:7/30/2014)... Albany, NewYork (PRWEB) July 30, 2014 ... population, the increase of personal health expenditure as ... government health care system, China diagnostic reagent industry ... reagents occupy over 90%. In 2013, Chinese in ... which RMB16.61 billion came from in vitro diagnostic ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... Pinnacle Biologics, a,private, full-service pharmaceutical and biotech ... agreement with pharmexx to expand sales,support activities in ... of the,agreement were not disclosed., Viren Grover, ... to conclude this agreement with pharmexx, which allows ...
... ON, July 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and six months ended May 31, 2008. All dollar ... At May 31, 2008, our cash and cash ... 29, 2008., The net loss for the second ...
... Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, ... V(TM) USA post-approval study, with six,hospital centers already recruiting and enrolling ... the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA ...
Cached Biology Technology:Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: